Sequelae of Lassa Fever: Postviral Cerebellar Ataxia.
Lassa fever
ataxia
neurodegenerative disorder
postviral
sequelae of Lassa fever
Journal
Open forum infectious diseases
ISSN: 2328-8957
Titre abrégé: Open Forum Infect Dis
Pays: United States
ID NLM: 101637045
Informations de publication
Date de publication:
Dec 2019
Dec 2019
Historique:
received:
23
10
2019
accepted:
02
12
2019
entrez:
28
12
2019
pubmed:
28
12
2019
medline:
28
12
2019
Statut:
epublish
Résumé
Lassa fever is a zoonotic disease endemic in some West African countries. It is exported to countries in America, Asia, and Europe. Antivirals against Lassa fever are important to provide a cure in patients with the disease and provide protection against it. In addition, due to the potential utilization of Lassa virus as a bioterrorism agent, vaccines against the disease can be utilized as a counterterrorism measure. Developing antiviral compounds and vaccines against the disease requires understanding of the pathogenesis of Lassa fever and its disease course, including the signs, symptoms, complications, and sequelae. An important sequela of Lassa fever is ataxia. A few cases of postviral ataxia following Lassa fever have been described in the literature. This review focuses on highlighting these cases, the gaps in scientific knowledge where further research is needed, and possible ways of diagnosing postviral ataxia after Lassa fever in resource-limited settings.
Identifiants
pubmed: 31879673
doi: 10.1093/ofid/ofz512
pii: ofz512
pmc: PMC6923636
doi:
Types de publication
Journal Article
Review
Langues
eng
Pagination
ofz512Subventions
Organisme : NIAID NIH HHS
ID : R01 AI129198
Pays : United States
Informations de copyright
© The Author(s) 2019. Published by Oxford University Press on behalf of Infectious Diseases Society of America.
Références
Nat Rev Microbiol. 2010 Sep;8(9):645-55
pubmed: 20706281
J Trop Med Hyg. 1992 Jun;95(3):197-201
pubmed: 1597876
Lancet. 2013 Jul 27;382(9889):363-5
pubmed: 23541538
Handb Clin Neurol. 2018;155:313-332
pubmed: 29891069
Case Rep Neurol Med. 2016;2016:1978461
pubmed: 27957363
Emerg Infect Dis. 2006 May;12(5):835-7
pubmed: 16704848
Lancet Neurol. 2010 Jan;9(1):94-104
pubmed: 20083040
Brain. 2002 May;125(5):961-8
pubmed: 11960886
Vaccine. 2009 Mar 18;27(13):1970-3
pubmed: 19186201
J Neuropathol Exp Neurol. 2000 Jul;59(7):561-74
pubmed: 10901227
Open Forum Infect Dis. 2016 Sep 20;3(4):ofw198
pubmed: 27975074
Int J Health Policy Manag. 2018 Mar 10;7(9):798-806
pubmed: 30316228
Acta Neuropathol. 2010 Jan;119(1):75-88
pubmed: 20033190
Trends Microbiol. 2012 Jun;20(6):282-90
pubmed: 22564250
Am J Trop Med Hyg. 1970 Jul;19(4):677-9
pubmed: 4987546
Am J Trop Med Hyg. 1970 Jul;19(4):680-91
pubmed: 4987547
J Child Neurol. 2003 May;18(5):309-16
pubmed: 12822814
Lancet Infect Dis. 2018 Jun;18(6):684-695
pubmed: 29523497
Mediators Inflamm. 2016;2016:8562805
pubmed: 27313404
J Infect Dis. 1987 Mar;155(3):456-64
pubmed: 3805773
BMJ. 1995 Sep 30;311(7009):857-9
pubmed: 7580496
Science. 1974 Jul 19;185(4147):263-5
pubmed: 4833828
Parasit Vectors. 2018 Jul 13;11(1):416
pubmed: 30005641
J Infect Dis. 2001 Aug 1;184(3):345-9
pubmed: 11443561
Clin Microbiol Rev. 2014 Oct;27(4):691-726
pubmed: 25278572
Niger J Clin Pract. 2017 Aug;20(8):1027-1035
pubmed: 28891549
J Virol. 1970 May;5(5):651-2
pubmed: 4986852
Hum Resour Health. 2017 May 12;15(1):32
pubmed: 28494782
Am J Trop Med Hyg. 1970 Jul;19(4):692-4
pubmed: 4987548
Nat Rev Immunol. 2011 May;11(5):318-29
pubmed: 21508982
J Virol. 2015 Dec 30;90(6):2920-7
pubmed: 26719273
Am J Trop Med Hyg. 1970 Jul;19(4):670-6
pubmed: 4246571
J Natl Med Assoc. 2006 May;98(5):758-64
pubmed: 16749652
J Neuroimmune Pharmacol. 2010 Sep;5(3):370-86
pubmed: 20401700